Recent Security Class Actions

AbbVie Inc. Common Stock (NYSE: ABBV)

Company Name:AbbVie Inc. Common Stock
Stock Symbol:NYSE: ABBV
Class Period Start:04/30/2021
Class Period End (inclusive):08/31/2021

The Complaint alleges that, throughout the Class Period, the Defendants made materially false and/or misleading statements, about the company’s business and operations. Specifically, the Complaint alleges Defendants misrepresented and/or failed to disclose that: (1) safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, Defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis. As a result of the alleged wrongful acts and omissions, AbbVie's securities have experienced a significant decline in market value and AbbVie investors have suffered significant damages.